ClinicalTrials.gg
CompletedNCT04308590GRADIENTUpdated Sep 4, 2025Results posted

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

A Phase 3 interventional study of Relacorilant and Placebo in Hypercortisolism, sponsored by Corcept Therapeutics. Completed at 45 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Corcept Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Cushing Syndrome by Corcept Therapeutics — none open to participants now, 1 under way, none of them phase 3. Cushing Syndrome · Corcept Therapeutics.

Enrollment
3rd of 11
137 · median 35
Started
2020
with 1 other
Phase 3
6 of 16
none open now
Registered
12th of 16
by date

Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 3, and was the 12th registered.

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

Browse Cushing Syndrome studies →

Open to participants now

None of the 16 studies in Cushing Syndrome by Corcept Therapeutics is open now. The open studies under Cushing Syndrome, anywhere →

Who these studies take

Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Cushing Syndrome by Corcept Therapeutics as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontrolled systolic hypertension (HTN).

Read the detailed description

The primary outcome measures of the study are 1) to assess the efficacy of relacorilant based on blood pressure control at Week 22 compared with placebo, and 2) to assess the safety of relacorilant based on adverse events. Patients will be randomized in a 1:1 ratio to treatment with relacorilant (active drug) or placebo. Patients will receive relacorilant or placebo for 22 weeks. Patients who complete the study may also be eligible to roll over into an extension study.

03

Conditions studied

  • Hypercortisolism

Keywords

  • Cushing syndrome
  • Cushing
  • Hypercortisolemia
  • Type 2 Diabetes
  • Impaired Glucose Intolerance
  • Hypertension
  • Adrenocorticotropic hormone
  • Primary Pigmented Nodular Adrenal Disease
  • Macronodular adrenal hyperplasia
  • Adrenal Adenoma
  • Adrenal Autonomy
  • Cortisol
  • Autonomous cortisol secretion
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Shows lack of cortisol suppression on dexamethasone suppression test
  • Suppressed or low early-morning adrenocorticotropic hormone (ACTH) levels
  • A radiologically confirmed adrenal lesion
  • Has IGT or DM
  • Has uncontrolled HTN

Exclusion criteria

Exclusion Criteria:

  • Has severe, uncontrolled HTN
  • Has poorly controlled DM
  • Has DM Type 1
  • Has significantly abnormal liver test results or severe renal insufficiency
  • Has uncontrolled, hypothyroidism or hyperthyroidism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Relacorilant

    Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.

    Drug: Relacorilant · Other: Placebo

  • Placebo comparator
    Placebo

    Patients will receive placebo matched to study drug once daily.

    Other: Placebo

Interventions

  • Relacorilant is supplied as blister-packed capsules for oral dosing. Relacorilant 400 mg dose consists of 4 relacorilant 100-mg capsules. Relacorilant 100-mg, 200-mg, and 300-mg doses are each given as a combination of 4 capsules containing relacorilant 100-mg and placebo as per the assigned dose.

    Also known as: CORT125134

  • OtherPlacebo

    Placebo is supplied as blister-packed capsules for oral dosing. Each dose consists of 4 capsules containing placebo.

06

What researchers measure

Primary outcomes

  1. Change in Average 24-hour SBP

    Blood pressure was measured by 24-hour ABPM. The 24-hour average SBP is reported.

    Time frame: Baseline and Week 22

  2. Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.

    Time frame: Baseline and up to Week 26

Secondary outcomes

  1. Change in Area Under the Concentration-time Curve of Blood Glucose (AUCglucose)

    AUCglucose was calculated based on results of the plasma 2-hour oGTT.

    Time frame: Before and at time intervals up to 2 hours post glucose drink at Baseline and Week 22

  2. Change in Average Diastolic Blood Pressure (DBP)

    Blood pressure was measured by 24-hour ABPM. Daytime average DBP was measured from 06:00 to 21:59. Nighttime average DBP was measure from 22:00 to 05:59.

    Time frame: Baseline and Week 22

  3. Change in Average Heart Rate (HR)

    Heart rate was measured by 24-hour ABPM. Daytime average HR was measured from 06:00 to 21:59. Nighttime average HR was measure from 22:00 to 05:59.

    Time frame: Baseline and Week 22

  4. Change in Average Daytime and Nighttime SBP

    Blood pressure was measured by 24-hour ABPM. Daytime average SBP was measured from 06:00 to 21:59. Nighttime average SBP was measure from 22:00 to 05:59.

    Time frame: Baseline and Week 22

  5. Change in Hemoglobin HbA1c for Patients With HbA1c ≥5.7% at Baseline

    Time frame: Baseline and Week 22

  6. Change in HbA1c for Patients With HbA1c ≥6.5% at Baseline

    Time frame: Baseline and Week 22

  7. Number of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL

    Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.

    Time frame: 2 hours post glucose drink at Week 22

  8. Number of Patients With IGT Who Achieved 2-hour oGTT Glucose <140 mg/dL

    Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.

    Time frame: 2 hours post glucose drink at Week 22

  9. Number of Patients With Any Dose Decrease in Antihypertensive Medication

    Time frame: Baseline and Week 22

  10. Number of Patients With Any Dose Decrease in Diabetes Medication

    Time frame: Baseline and Week 22

  11. Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication

    Time frame: Baseline and Week 22

  12. Number of Patients With Any Dose Increase or Switch in Diabetes Medication

    Time frame: Baseline and Week 22

  13. Number of Patients With HbA1c ≥6.5% at Baseline Who Achieved HbA1c <6.5%

    Time frame: Baseline and Week 22

  14. Number of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg)

    Blood pressure was measured by 24-hour ABPM Test. Reported is the number of patients with HTN at Baseline who achieved SBP \<130 mm Hg at Week 22.

    Time frame: Baseline and Week 22

  15. Number of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg

    Blood pressure was measured by 24-hour ABPM. Reported is the number of patients with HTN at Baseline who achieved at least a 5 mm Hg reduction in 24-hour average SBP at Week 22.

    Time frame: Baseline and Week 22

07

Results

Posted Aug 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneRelacorilantPlacebo
Started6869
Completed4361
Not completed258
Withdrew: Adverse event122
Withdrew: Withdrawal by subject104
Withdrew: Death10
Withdrew: Lost to follow-up11
Withdrew: Physician decision10
Withdrew: Subject does not want to continue with pi01

Outcome measures

PrimaryChange in Average 24-hour SBP

Blood pressure was measured by 24-hour ABPM. The 24-hour average SBP is reported.

Time frame:
Baseline and Week 22
Reported as:
Least squares mean · mm Hg
Change in Average 24-hour SBP
mm HgRelacorilantPlacebo
Change in Average 24-hour SBP-5.56 (-10.459 to -0.659)-2.89 (-6.794 to 1.006)
Statistical analysis
  • Relacorilant vs Placebo · Mixed Models Analysis · p = 0.4160 · Least squares mean difference: -2.67 · 95% CI -9.096 to 3.766
PrimaryNumber of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.
Time frame:
Baseline and up to Week 26
Reported as:
Count of participants · Participants
Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.
ParticipantsRelacorilantPlacebo
Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.6760
SecondaryChange in Area Under the Concentration-time Curve of Blood Glucose (AUCglucose)

AUCglucose was calculated based on results of the plasma 2-hour oGTT.

Time frame:
Before and at time intervals up to 2 hours post glucose drink at Baseline and Week 22
Reported as:
Least squares mean · hours x mmol/L
Change in Area Under the Concentration-time Curve of Blood Glucose (AUCglucose)
hours x mmol/LRelacorilantPlacebo
Change in Area Under the Concentration-time Curve of Blood Glucose (AUCglucose)-1.566 (-3.472 to 0.340)1.008 (-0.661 to 2.676)
SecondaryChange in Average Diastolic Blood Pressure (DBP)

Blood pressure was measured by 24-hour ABPM. Daytime average DBP was measured from 06:00 to 21:59. Nighttime average DBP was measure from 22:00 to 05:59.

Time frame:
Baseline and Week 22
Reported as:
Least squares mean · mm Hg
Change in Average Diastolic Blood Pressure (DBP)
mm HgRelacorilantPlacebo
24-hour Average-3.3 (-6.1 to -0.5)-1.4 (-3.8 to 0.9)
Daytime Average-3.1 (-6.0 to -0.1)-1.0 (-3.5 to 1.6)
Nighttime Average-3.0 (-6.4 to 0.5)-0.6 (-3.5 to 2.4)
SecondaryChange in Average Heart Rate (HR)

Heart rate was measured by 24-hour ABPM. Daytime average HR was measured from 06:00 to 21:59. Nighttime average HR was measure from 22:00 to 05:59.

Time frame:
Baseline and Week 22
Reported as:
Least squares mean · Beats per minute
Change in Average Heart Rate (HR)
Beats per minuteRelacorilantPlacebo
24-hour Average2.0 (-0.4 to 4.5)-2.0 (-4.1 to 0.1)
Daytime Average1.7 (-1.1 to 4.5)-1.5 (-3.9 to 0.9)
Nighttime Average2.2 (-0.4 to 4.7)-2.7 (-4.9 to -0.5)
SecondaryChange in Average Daytime and Nighttime SBP

Blood pressure was measured by 24-hour ABPM. Daytime average SBP was measured from 06:00 to 21:59. Nighttime average SBP was measure from 22:00 to 05:59.

Time frame:
Baseline and Week 22
Reported as:
Least squares mean · mm Hg
Change in Average Daytime and Nighttime SBP
mm HgRelacorilantPlacebo
Daytime Average-4.5 (-9.0 to -0.1)-2.5 (-6.3 to 1.4)
Nighttime Average-4.6 (-9.9 to 0.6)-3.0 (-7.5 to 1.4)
SecondaryChange in Hemoglobin HbA1c for Patients With HbA1c ≥5.7% at Baseline
Time frame:
Baseline and Week 22
Reported as:
Least squares mean · Percentage
Change in Hemoglobin HbA1c for Patients With HbA1c ≥5.7% at Baseline
PercentageRelacorilantPlacebo
Change in Hemoglobin HbA1c for Patients With HbA1c ≥5.7% at Baseline-0.29 (-0.49 to -0.09)0.00 (-0.17 to 0.17)
SecondaryChange in HbA1c for Patients With HbA1c ≥6.5% at Baseline
Time frame:
Baseline and Week 22
Reported as:
Least squares mean · Percentage
Change in HbA1c for Patients With HbA1c ≥6.5% at Baseline
PercentageRelacorilantPlacebo
Change in HbA1c for Patients With HbA1c ≥6.5% at Baseline-0.57 (-1.00 to -0.14)-0.19 (-0.52 to 0.14)
SecondaryNumber of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL

Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.

Time frame:
2 hours post glucose drink at Week 22
Reported as:
Count of participants · Participants
Number of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL
ParticipantsRelacorilantPlacebo
Number of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL10
SecondaryNumber of Patients With IGT Who Achieved 2-hour oGTT Glucose <140 mg/dL

Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.

Time frame:
2 hours post glucose drink at Week 22
Reported as:
Count of participants · Participants
Number of Patients With IGT Who Achieved 2-hour oGTT Glucose <140 mg/dL
ParticipantsRelacorilantPlacebo
Number of Patients With IGT Who Achieved 2-hour oGTT Glucose <140 mg/dL67
SecondaryNumber of Patients With Any Dose Decrease in Antihypertensive Medication
Time frame:
Baseline and Week 22
Reported as:
Count of participants · Participants
Number of Patients With Any Dose Decrease in Antihypertensive Medication
ParticipantsRelacorilantPlacebo
Number of Patients With Any Dose Decrease in Antihypertensive Medication75
SecondaryNumber of Patients With Any Dose Decrease in Diabetes Medication
Time frame:
Baseline and Week 22
Reported as:
Count of participants · Participants
Number of Patients With Any Dose Decrease in Diabetes Medication
ParticipantsRelacorilantPlacebo
Number of Patients With Any Dose Decrease in Diabetes Medication00
SecondaryNumber of Patients With Any Dose Increase or Switch in Antihypertensive Medication
Time frame:
Baseline and Week 22
Reported as:
Count of participants · Participants
Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication
ParticipantsRelacorilantPlacebo
Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication15
SecondaryNumber of Patients With Any Dose Increase or Switch in Diabetes Medication
Time frame:
Baseline and Week 22
Reported as:
Count of participants · Participants
Number of Patients With Any Dose Increase or Switch in Diabetes Medication
ParticipantsRelacorilantPlacebo
Number of Patients With Any Dose Increase or Switch in Diabetes Medication43
SecondaryNumber of Patients With HbA1c ≥6.5% at Baseline Who Achieved HbA1c <6.5%
Time frame:
Baseline and Week 22
Reported as:
Count of participants · Participants
Number of Patients With HbA1c ≥6.5% at Baseline Who Achieved HbA1c <6.5%
ParticipantsRelacorilantPlacebo
Number of Patients With HbA1c ≥6.5% at Baseline Who Achieved HbA1c <6.5%34
SecondaryNumber of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg)

Blood pressure was measured by 24-hour ABPM Test. Reported is the number of patients with HTN at Baseline who achieved SBP \<130 mm Hg at Week 22.

Time frame:
Baseline and Week 22
Reported as:
Count of participants · Participants
Number of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg)
ParticipantsRelacorilantPlacebo
Number of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg)913
SecondaryNumber of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg

Blood pressure was measured by 24-hour ABPM. Reported is the number of patients with HTN at Baseline who achieved at least a 5 mm Hg reduction in 24-hour average SBP at Week 22.

Time frame:
Baseline and Week 22
Reported as:
Count of participants · Participants
Number of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg
ParticipantsRelacorilantPlacebo
Number of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg1013

Adverse events

Collected over Up to Week 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Relacorilant1/68 (1.5%)15/68 (22.1%)65/68 (95.6%)
Placebo0/69 (0%)4/69 (5.8%)60/69 (87%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventRelacorilantPlacebo
DyspnoeaRespiratory, thoracic and mediastinal disorders2/680/69
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/680/69
Acral lentiginous melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/680/69
Acute coronary syndromeCardiac disorders1/680/69
Acute myocardial infarctionCardiac disorders1/681/69
Bladder transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/680/69
Coronary artery stenosisCardiac disorders1/680/69
Foot fractureInjury, poisoning and procedural complications1/680/69
Hepatic enzyme increasedInvestigations1/680/69
Localised infectionInfections and infestations1/680/69
Most frequent other events
Showing 10 of 34
Most frequent other events
EventRelacorilantPlacebo
Back painMusculoskeletal and connective tissue disorders21/689/69
FatigueGeneral disorders16/6810/69
Abdominal pain upperGastrointestinal disorders14/683/69
ArthralgiaMusculoskeletal and connective tissue disorders8/6814/69
NauseaGastrointestinal disorders13/688/69
Pain in extremityMusculoskeletal and connective tissue disorders13/685/69
Abdominal painGastrointestinal disorders12/682/69
HeadacheNervous system disorders7/6812/69
DizzinessNervous system disorders10/684/69
DiarrhoeaGastrointestinal disorders9/686/69

Baseline characteristics

The analysis population was patients in the Intent-to-treat (ITT) Population which included all randomized patients, even if they did not receive any study treatment.

Age, Continuous
Age, Continuous(years)RelacorilantPlaceboTotal
Mean62.5 ± 9.1163.0 ± 9.0062.7 ± 9.02
Sex: Female, Male
Sex: Female, Male(Participants)RelacorilantPlaceboTotal
Female504999
Male182038
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RelacorilantPlaceboTotal
Hispanic or Latino4610
Not Hispanic or Latino6463127
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RelacorilantPlaceboTotal
American Indian or Alaska Native011
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American314
White6365128
More than one race000
Unknown or Not Reported011
Hypertension (HTN) only
Hypertension (HTN) only(Participants)RelacorilantPlaceboTotal
Count of participants202141
Diabetes mellitus (DM) or impaired glucose tolerance (IGT) only
Diabetes mellitus (DM) or impaired glucose tolerance (IGT) only(Participants)RelacorilantPlaceboTotal
Count of participants262753
HTN and DM/IGT
HTN and DM/IGT(Participants)RelacorilantPlaceboTotal
Count of participants222143
08

Study locations

45 sites
  • Site 27
    Birmingham, Alabama 35294, United States
  • Site 17
    Stanford, California 94305, United States
  • Site 53
    Torrance, California 90502, United States
  • Site 07
    Atlanta, Georgia 30318, United States
  • Site 16
    Indianapolis, Indiana 46202, United States
  • Site 09
    Metairie, Louisiana 70006, United States
  • Site 36
    Baltimore, Maryland 21287, United States
  • Site 11
    Fall River, Massachusetts 02721, United States
  • Site 33
    Rochester, Minnesota 55905, United States
  • Site 06
    Jackson, Mississippi 39202, United States
  • Site 54
    Reno, Nevada 89511, United States
  • Site 10
    Jamaica, New York 11432, United States
  • Site 44
    New York, New York 10021, United States
  • Site 01
    Wilmington, North Carolina 28401, United States
  • Site 30
    Cleveland, Ohio 44195, United States
  • Site 21
    Columbus, Ohio 43201-3209, United States
  • Site 02
    Summerville, South Carolina 29485, United States
  • Site 20
    Dallas, Texas 75390, United States
  • Site 03
    El Paso, Texas 79935, United States
  • Site 05
    Fort Worth, Texas 76132, United States
  • Site 08
    Houston, Texas 77079, United States
  • Site 15
    Spokane, Washington 99202, United States
  • Site 25
    Vienna, State of Vienna 1090, Austria
  • Site 22
    Sofia, 01431, Bulgaria
  • Site 50
    Munich, Bavaria 80336, Germany
  • Site 46
    Würzburg, 97080, Germany
  • Site 32
    Ramat Gan, 5265601, Israel
  • Site 23
    Tel Aviv, Israel
  • Site 40
    Milan, Milano 20122, Italy
  • Site 31
    Rome, Roma 00189, Italy
  • Site 43
    Orbassano, Torino, Italy
  • Site 34
    Milan, Italy
  • Site 28
    Naples, 80131, Italy
  • Site 51
    Padova, 35128, Italy
  • Site 37
    Rome, 00161, Italy
  • Site 52
    Torino, 10126, Italy
  • Site 48
    Gliwice, 44-102, Poland
  • Site 47
    Krakow, 31-501, Poland
  • Site 35
    Lublin, Poland
  • Site 42
    Bucharest, 010825, Romania
  • Site 38
    Bucharest, 011863, Romania
  • Site 41
    Bucharest, 011863, Romania
  • Site 14
    Málaga, 29006, Spain
  • Site 13
    Seville, 41013, Spain
  • Site 26
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Sep 2024, 49 months.

Results were first posted in Aug 2025, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2020
First posted
Mar 16, 2020
StartActual
Jul 27, 2020
Primary completionActual
Sep 19, 2024
CompletionActual
Sep 19, 2024
Results first posted
Aug 3, 2025
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04308590
Responsible party
Sponsor
First posted
Mar 16, 2020
Start date
Jul 27, 2020
Primary completion
Sep 19, 2024
Completion
Sep 19, 2024
Results posted
Aug 3, 2025
Last update
Sep 4, 2025

Study contacts

Andreas Moraitis, MD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relacorilant

Start the discussion